The announcement reads like a research grant, but ADVOCATE is structured more like a government contract with delivery requirements. Six teams have been selected, timelines are embedded, an external evaluator (Johns Hopkins University Applied Physics Laboratory) is already appointed, and the FDA is co-developing the regulatory framework that will govern the output. This is not a grant that produces a paper. It is a procurement that is expected to produce an authorized clinical AI system.

The difference matters for every company building autonomous clinical AI. ADVOCATE's structure establishes the first formal deadline for the FDA to build and publish a regulatory framework for prescriptive agentic AI in a high-risk clinical setting. Whatever emerges from that process in 2027 and 2028 will likely govern agentic clinical AI far beyond cardiovascular care. Here is what the program actually contains, who the players are, and what the downstream regulatory and commercial implications look like.

In this deep dive, we are going to look at:

  • Why this matters now: the regulatory gap ADVOCATE is forcing the FDA to close

  • What actually happened: the six teams, their roles, and the program structure

  • The obvious read versus the deeper signal

  • The agentic clinical AI landscape: who else is in this space and what ADVOCATE changes

  • The Evidence Ladder: where autonomous clinical AI currently sits

  • Bottom-up economics: who pays and who earns in an agentic care model

  • The HealthTech Investor's Signal

  • The strongest counter-thesis

  • Three to five observable milestones to track

  • The bottom line for health system leaders and technology investors